Jane Street Group LLC Lowers Stake in REGENXBIO Inc. (NASDAQ:RGNX)

Jane Street Group LLC lessened its holdings in REGENXBIO Inc. (NASDAQ:RGNX) by 48.1% in the 3rd quarter, Holdings Channel.com reports. The firm owned 38,776 shares of the biotechnology company’s stock after selling 35,994 shares during the quarter. Jane Street Group LLC’s holdings in REGENXBIO were worth $407,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. FMR LLC raised its position in REGENXBIO by 166.8% during the third quarter. FMR LLC now owns 2,649 shares of the biotechnology company’s stock worth $28,000 after acquiring an additional 1,656 shares during the period. nVerses Capital LLC increased its stake in shares of REGENXBIO by 183.3% during the third quarter. nVerses Capital LLC now owns 3,400 shares of the biotechnology company’s stock worth $36,000 after purchasing an additional 2,200 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its position in shares of REGENXBIO by 64.3% during the 3rd quarter. China Universal Asset Management Co. Ltd. now owns 9,506 shares of the biotechnology company’s stock worth $100,000 after purchasing an additional 3,720 shares during the last quarter. Arizona State Retirement System boosted its holdings in REGENXBIO by 20.6% in the 2nd quarter. Arizona State Retirement System now owns 11,669 shares of the biotechnology company’s stock worth $137,000 after buying an additional 1,997 shares during the last quarter. Finally, Erste Asset Management GmbH purchased a new stake in REGENXBIO during the 3rd quarter worth approximately $140,000. Institutional investors and hedge funds own 88.08% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Raymond James restated an “outperform” rating and issued a $18.00 target price on shares of REGENXBIO in a research report on Thursday, October 10th. Morgan Stanley reaffirmed an “overweight” rating and set a $22.00 target price on shares of REGENXBIO in a research note on Friday, November 15th. Chardan Capital reiterated a “buy” rating and issued a $52.00 target price on shares of REGENXBIO in a research report on Wednesday, November 20th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $35.00 price objective on shares of REGENXBIO in a research note on Wednesday, December 11th. Finally, StockNews.com raised shares of REGENXBIO from a “sell” rating to a “hold” rating in a research note on Friday, September 20th. Two research analysts have rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. According to MarketBeat.com, REGENXBIO presently has an average rating of “Moderate Buy” and an average price target of $35.27.

REGENXBIO Stock Performance

RGNX stock opened at $8.36 on Wednesday. REGENXBIO Inc. has a one year low of $7.14 and a one year high of $28.80. The firm has a market cap of $414.20 million, a PE ratio of -1.66 and a beta of 1.28. The firm’s 50 day moving average price is $9.03 and its 200-day moving average price is $10.71.

REGENXBIO Profile

REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company’s products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.